SCHEMBL4031391

SCHEMBL4031391

Oc1ccc(-c2nn(Cc3ccccc3)c3ccc(F)cc23)cc1O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 3/20 0.47
KDM4C Q9H3R0 1/20 0.45
PTGDR2 Q9Y5Y4 3/20 0.45
ESR1 P03372 2/20 0.44
F2RL3 Q96RI0 1/20 0.43
MEN1 O00255 1/20 0.43
POLB P06746 1/20 0.43
KMT2A Q03164 1/20 0.43
RORC P51449 2/20 0.43
ALDH1A1 P00352 2/20 0.40
PDE4A P27815 1/20 0.40
PDE4B Q07343 1/20 0.40
PDE4C Q08493 1/20 0.40
PDE4D Q08499 1/20 0.40
BUB1 O43683 1/20 0.40
KDM4E B2RXH2 1/20 0.40
NPC1 O15118 1/20 0.40
GMNN O75496 1/20 0.40
LMNA P02545 1/20 0.40
TP53 P04637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4026862 0.86 F2RL3 (0.56) PDE5AESR1F2RL3KMT2ARORC
SCHEMBL4034694 0.84 ESR1 (0.47) PDE5AESR1F2RL3MEN1KMT2A
SCHEMBL4028787 0.84 ESR1 (0.47) PDE5AESR1F2RL3MEN1KMT2A
SCHEMBL4035132 0.80 ESR1 (0.56) ESR1F2RL3RORCALDH1A1PDE4A
SCHEMBL4030028 0.80 ESR1 (0.47) PDE5AESR1F2RL3MEN1KMT2A
SCHEMBL4025988 0.76 NAMPT (0.48) KDM4CESR1MEN1POLBKMT2A
SCHEMBL4031338 0.76 ESR1 (0.75) ESR1F2RL3MEN1KMT2ARORC
SCHEMBL4029651 0.74 ESR1 (0.77) ESR1F2RL3RORCALDH1A1PDE4A
SCHEMBL15792198 0.74 KDM4C (0.49) PDE5AKDM4CPTGDR2MEN1POLB
SCHEMBL5560137 0.74 PDE5A (0.84) PDE5AKDM4CPTGDR2MEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1542976-B1 SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES WYETH CORP (US) 2009-02-04 EP disclosed
US-20070225349-A1 Substituted 4-(Indazol-3-yl)phenols WYETH (US) 2007-09-27 US disclosed
US-7241791-B2 Substituted 4-(indazol-3-yl)phenols WYETH (US) 2007-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225349-A1 Substituted 4-(Indazol-3-yl)phenols INSR, TNNI3, INSRR PDE5A 1359/4885KDM4C 673/4885PTGDR2 506/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.